Publications

Publications pour l'équipe Oncostat

Titre Publication Type Publication year Auteur
Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer journalArticle 2019 Le Rhun, E.; Wallet, J.; Mailliez, A.; Le Deley, M. C.; Rodrigues, I.; Boulanger, T.; Lorgis, V.; Barriere, J.; Robin, Y. M.; Weller, M.; Bonneterre, J.
Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma journalArticle 2015 Hadoux, J.; Malka, D.; Planchard, D.; Scoazec, J. Y.; Caramella, C.; Guigay, J.; Boige, V.; Leboulleux, S.; Burtin, P.; Berdelou, A.; Loriot, Y.; Duvillard, P.; Chougnet, C. N.; Déandréis, D.; Schlumberger, M.; Borget, I.; Ducreux, M.; Baudin, E.
[Editorial] journalArticle 2018 Perrier, L.
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination journalArticle 2016 Boutros, C.; Tarhini, A.; Routier, E.; Lambotte, O.; Ladurie, F. L.; Carbonnel, F.; Izzeddine, H.; Marabelle, A.; Champiat, S.; Berdelou, A.; Lanoy, E.; Texier, M.; Libenciuc, C.; Eggermont, A. M.; Soria, J. C.; Mateus, C.; Robert, C.
Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma journalArticle 2015 Izzedine, H.; Derosa, L.; Le Teuff, G.; Albiges, L.; Escudier, B.
A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg Type journalArticle 2018 Beylot-Barry, M.; Mermin, D.; Maillard, A.; Bouabdallah, R.; Bonnet, N.; Duval-Modeste, A. B.; Mortier, L.; Ingen-Housz-Oro, S.; Ram-Wolff, C.; Barete, S.; Dalle, S.; Maubec, E.; Quereux, G.; Templier, I.; Bagot, M.; Grange, F.; Joly, P.; Vergier, B.; Vially, P. J.; Gros, A.; Pham-Ledard, A.; Frison, E.; Merlio, J. P.
Can postoperative radiotherapy be omitted in localised standard-risk Ewing sarcoma? An observational study of the Euro-E.W.I.N.G group journalArticle 2016 Foulon, S.; Brennan, B.; Gaspar, N.; Dirksen, U.; Jeys, L.; Cassoni, A.; Claude, L.; Seddon, B.; Marec-Berard, P.; Whelan, J.; Paulussen, M.; Streitbuerger, A.; Oberlin, O.; Juergens, H.; Grimer, R.; Le Deley, M. C.
Quality-of-Life Assessment in French Patients With Metastatic Melanoma in Real Life journalArticle 2020 M;Kandel, S;Dalle, A;Bardet, C;Allayous, L;Mortier, C;Dutriaux, B;Guillot, M;Leccia, S;Dalac, D;Legoupil, P;Saiag, H;Montaudie, JP;Arnault, F;B.Possenti, JJ;Grob, J;DeQuatrebarbes, M;Beylot-Barry, T;Lesimple, F;Aubin, E;Maubec, F;Granel-Brocard, PE;Stoebner, A;Dupuy, B;Dreno, S;Michiels, C;Lebbe, I;Borget
A Systematic Review of the Level of Evidence in Economic Evaluations of Medical Devices: The Example of Vertebroplasty and Kyphoplasty journalArticle 2015 Martelli, N.; Devaux, C.; van den Brink, H.; Pineau, J.; Prognon, P.; Borget, I.
Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door journalArticle 2018 Verlingue, L.; Hollebecque, A.; Lacroix, L.; Postel-Vinay, S.; Varga, A.; El Dakdouki, Y.; Baldini, C.; Balheda, R.; Gazzah, A.; Michot, J. M.; Marabelle, A.; Mir, O.; Arnedos, M.; Rouleau, E.; Solary, E.; De Baere, T.; Angevin, E.; Armand, J. P.; Michiels, S.; André, F.; Deutsch, E.; Scoazec, J. Y.; Soria, J. C.; Massard, C.
Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors journalArticle 2017 Bahleda, R.; Le Deley, M. C.; Bernard, A.; Chaturvedi, S.; Hanley, M.; Poterie, A.; Gazzah, A.; Varga, A.; Touat, M.; Deutsch, E.; Massard, C.; Van De Velde, H.; Hollebecque, A.; Sallansonnet-Froment, M.; Ricard, D.; Taillia, H.; Angevin, E.; Ribrag, V.; Soria, J. C.
Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours journalArticle 2016 Gizzi, M.; Oberic, L.; Massard, C.; Poterie, A.; Gwenael, L. T.; Loriot, Y.; Albiges, L.; Baciarello, G.; Michels, J.; Bossi, A.; Blanchard, P.; Escudier, B.; Fizazi, K.
How to Model Survival In Cost-Effectiveness Analysis? Differences Between Markov and Partitioned Survival Analysis Models journalArticle 2015 Minacori, R.; Bonastre, J.; Lueza, B.; Marguet, S.; Levy, P.
Antiangiogenic Tyrosine Kinase Inhibitors: Occurrence and Risk Factors of Hemoptysis in Refractory Thyroid Cancer journalArticle 2016 Lamartina, L.; Ippolito, S.; Danis, M.; Bidault, F.; Borget, I.; Berdelou, A.; Al Ghuzlan, A.; Hartl, D.; Blanchard, P.; Terroir, M.; Deandreis, D.; Schlumberger, M.; Baudin, E.; Leboulleux, S.
The cost of thromboembolic events in hospitalized patients with breast or prostate cancer in France journalArticle 2015 Scotte, F.; Martelli, N.; Vainchtock, A.; Borget, I.
Adjuvant chemotherapy for resected early-stage non-small cell lung cancer journalArticle 2015 Burdett, S.; Pignon, J. P.; Tierney, J.; Tribodet, H.; Stewart, L.; Le Pechoux, C.; Aupérin, A.; Le Chevalier, T.; Stephens, R. J.; Arriagada, R.; Higgins, J. P.; Johnson, D. H.; Van Meerbeeck, J.; Parmar, M. K.; Souhami, R. L.; Bergman, B.; Douillard, J. Y.; Dunant, A.; Endo, C.; Girling, D.; Kato, H.; Keller, S. M.; Kimura, H.; Knuuttila, A.; Kodama, K.; Komaki, R.; Kris, M. G.; Lad, T.; Mineo, T.; Piantadosi, S.; Rosell, R.; Scagliotti, G.; Seymour, L. K.; Shepherd, F. A.; Sylvester, R.; Tada, H.; Tanaka, F.; Torri, V.; Waller, D.; Liang, Y.
Phase I–II trial designs: how early should efficacy guide the dose recommendation process? journalArticle 2018 Paoletti, X; Postel-Vinay, S
Erratum to: Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis journalArticle 2016 Lueza, B.; Rotolo, F.; Bonastre, J.; Pignon, J. P.; Michiels, S.
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial journalArticle 2015 Salgado, R.; Denkert, C.; Campbell, C.; Savas, P.; Nuciforo, P.; Aura, C.; de Azambuja, E.; Eidtmann, H.; Ellis, C. E.; Baselga, J.; Piccart-Gebhart, M. J.; Michiels, S.; Bradbury, I.; Sotiriou, C.; Loi, S.
Treating Metastatic Prostate Cancer With Local Therapies: Is It Still Wishful Thinking? journalArticle 2018 Bibault, J. E.; Blanchard, P.
MRI-guided brachytherapy in locally advanced cervical cancer: Small bowel [Formula: see text] and [Formula: see text] are not predictive of late morbidity journalArticle 2016 Petit, C.; Dumas, I.; Chargari, C.; Martinetti, F.; Maroun, P.; Doyeux, K.; Tailleur, A.; Haie-Meder, C.; Mazeron, R.
Daily Biopsy Diagnosis in Surgical Pathology: Concordance Between Light Microscopy and Whole-Slide Imaging in Real-Life Conditions journalArticle 2018 Villa, I.; Mathieu, M. C.; Bosq, J.; Auperin, A.; Pomerol, J. F.; Lacroix-Triki, M.; Scoazec, J. Y.; Dartigues, P.
Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): A single-institution experience journalArticle 2016 Bluthgen, M. V.; Boutros, C.; Fayard, F.; Remon, J.; Planchard, D.; Besse, B.
Revisiting vascular contraindications for transoral robotic surgery for oropharyngeal cancer journalArticle 2018 Gorphe, P.; Auperin, A.; Honart, J. F.; Ton Van, J.; El Bedoui, S.; Bidault, F.; Temam, S.; Kolb, F.; Qassemyar, Q.
[Network meta-analyses: Interest and limits in oncology] journalArticle 2016 Ribassin-Majed, L.; Pignon, J. P.; Michiels, S.; Blanchard, P.
Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas journalArticle 2018 Delahousse, J.; Verlingue, L.; Broutin, S.; Legoupil, C.; Touat, M.; Doucet, L.; Ammari, S.; Lacroix, L.; Ducreux, M.; Scoazec, J. Y.; Malka, D.; Paci, A.; Hollebecque, A.
In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies? journalArticle 2017 Aspeslagh, S.; Matias, M.; Palomar, V.; Dercle, L.; Lanoy, E.; Soria, J. C.; Postel-Vinay, S.
[Reirradiation for head and neck squamous cell carcinoma: Indications and results] journalArticle 2019 Biau, J.; Moreau, J.; Blanchard, P.; Thariat, J.; Miroir, J.; Lapeyre, M.
Bevacizumab versus anti-epidermal growth factor receptor in first-line metastatic colorectal cancer. A meta-analysis: The last building block? journalArticle 2016 Ducreux, M.; Pignon, J. P.
Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries journalArticle 2015 Cain, L. E.; Phillips, A.; Olson, A.; Sabin, C.; Jose, S.; Justice, A.; Tate, J.; Logan, R.; Robins, J. M.; Sterne, J. A.; van Sighem, A.; Reiss, P.; Young, J.; Fehr, J.; Touloumi, G.; Paparizos, V.; Esteve, A.; Casabona, J.; Monge, S.; Moreno, S.; Seng, R.; Meyer, L.; Pérez-Hoyos, S.; Muga, R.; Dabis, F.; Vandenhende, M. A.; Abgrall, S.; Costagliola, D.; Hernán, M. A.
[Economic analysis of multinational clinical trials in oncology] journalArticle 2018 Lejeune, C.; Lueza, B.; Bonastre, J.
Factors which modulate the rates of skeletal muscle mass loss in non-small cell lung cancer patients: a pilot study journalArticle 2017 Atlan, P.; Bayar, M. A.; Lanoy, E.; Besse, B.; Planchard, D.; Ramon, J.; Raynard, B.; Antoun, S.
Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care journalArticle 2015 Schneider, D.; Bianchini, G.; Horgan, D.; Michiels, S.; Witjes, W.; Hills, R.; Plun-Favreau, J.; Brand, A.; Lawler, M.